08 July 2025   Despite extensive biomedical research, disease-modifying treatments for human neurodevelopmental disorders such as autism spectrum disorder and schizophrenia are still lacking. Neurology and psychiatry are consistently the lowest success categories in drug development, with a 95-97% failure rate in clinical trials. Owing to inter-species differences in brain anatomy and physiology, animal models do not recapitulate human-specific molecular and cellular pathways